The effect ofprostaglandin Ex (PGEO on cerebral blood flow (CBF) was studied in 10 patients with chronic cerebral infarction. Regional cerebral blood flow (rCBF) was measured by single photon emission computed tomography before and after they received PGEj 120 |ig daily for 2 weeks. The rCBF of the brainstem, cerebellum, and frontal, temporal, and parietal lobes increased significantly after PGEXadministration. PGEjalso significantly increased the rCBF of the noninfarcted area adjacent to infarction. The results indicate that PGEXincreases the CBFof patients with chronic cerebral infarction without causing the intracerebral steal phenomenon.
Introduction
Prostaglandins are locally acting hormones that are derived from unsaturated fatty acids. Prostaglandin Ex (PGEj) is produced from dishomo-y-linoleic acid and is metabolized by 15-hydroxy prostaglandin dehydrogenase. PGEj is built on the skeleton of prostanoic acid whosemolecular configuration consists of cyclopentan and two side chains. Bergstromand Sjovall successfully purified PGEj in 1957 (1). PGEj has many potent pharmacologic actions, such as inhibition of platelet aggregation and vasodilator activity. PGEj has been given clinically, since Carlson et al first reported that the intravenous infusion of PGEj in patients with severe peripheral vascular disease achieves striking improvement (2). Although the effect of PGEj has been studied experimentally, little is known about its clinical effects on cerebral blood flow (CBF).
Subjects and Methods
Ten Japanese with chronic cerebral infarction participated in the present study. They were 7 males and 3 females aged 48 to 81, mean 70 ± 9.8 years. The diagnosis of cerebral infarction was madeby a neurologist in all cases and was confirmed by computed tomography and/or magnetic resonance imaging brain scans. All patients gave their informed consent and the ethics committee of our hospital approved the present study. Patients with a history of intracerebral bleeding, intracranial tumor, head trauma, subarachnoid hemorrhage, or hemorrhagic brain infarction and those being treated with sulfonylureas were excluded. Table 1 shows the profile of the 10 patients. Five patients had right cerebral infarction, 2 had left cerebral infarction, and 3 had multiple cerebral infarctions in both hemispheres. PGEt in 100 ml of physiologic saline was given by intravenous infusion to the patients at a dose of 60 jig twice a day for 2 weeks.
The patients underwent single photon emission computed tomography (SPECT) at rest before and after administration of PGEi.The ears were not plugged, but the eyes were closed. The second SPECTscan was performed within 3 days after the end of PGEi administration.
Regional cerebral blood flow (rCBF) was measured by the method described by Iida et al (3) . The SPECT scan, which utilized a Headtome-SET080 (Simadzu Co., Kyoto), was performed after the intravenous injection of 222 MBq of N-isopropyl-p-[123I]iodoamphetamine (123I-IMP) at a constant fusion rate for a period of 1.0 minute. Radioactivity of the arterial blood sampled from the left brachial artery 10 minutes after the start of the injection, was measured by a scintillator.
Scanning CBFbegan 25 minutes after the injection of 123I-IMP; scanning time was 30 minutes.
Images reflecting CBF were created by the SPECT autoradiographic method (3). Using a standard distribution volume (Vd: Vd = 32 ml/ml) and standard input functions which were obtained from a preliminary dynamic study of 6 normal subjects in advance, CBFwas calculated. CBFimages were obtained from six slices of brain parallel to the orbitomeatal plane (OM) (OM+20, OM+30, OM+40, OM+50, OM+65, and 
Results

Somepatients complainedof vascular pain (4 patients) or
redness at the site of injection (2 patients), but all of the patients remainedin the study. Therewasno changein the administration of the other drugs during the present study. The symptoms did not worsenduring or after the administration of PGE2.
Thoughthere wasno changein neurologicfindings, the subjective symptoms improvedin 2 patients (Case6; improvement of motorimpairment,Case 8; improvementof disturbance of concentration). Theintravenous administration of PGEl9120 |ig daily for 2 weeks, significantly increased the rCBFin the brainstem, cerebellum, and frontal, temporal, and parietal lobes ( Table 2 , Fig. 1 ). The rCBFof the occipital lobe, thalamus, and striatum also tendedto increase, but not significantly. The administration of PGEjsignificantly increased the rCBFof the non-infarcted area adj acent to infarction. A representative case is presented below. The patient, a 66-year-old Japanese man(Case 2), complained of gait disturbance, muscleweakness, and sensory disturbance of the left lower extremity. Hehad suffered from diabetes mellitus for 26 years. T2-weightedmagneticresonance scans showeda high signal intensity lesion in the bilateral basal ganglia andright coronaradiata. Onexamination,the patient' s extremitieswerenormotonic, with increasedreflexes in the left upperextremitybut no evidenceof pathologicreflex, and left hemi-hypesthesia to all sensations. Musclestrength wasdiminished in the left lowerextremity. Thepatient' s gait wasspastic andhe requiredassistance in walking.Thescores for verbal, performance, and total IQ were 109, 90, and 100, respectively on a WechslerAdult Intelligence Scale-Revised test. Figure 2 showsCBFimagesin this patient. Theintravenous administration of PGEiincreased rCBFof all regions. The administration of PGEjalso increased the rCBFin the non-infarcted area adjacent to the infarction.
Discussion
PGEjpossesses a powerfulvasodilatory activity, producing a diffuse dilatation of arterioles, metarterioles, precapillary sphincters, and muscularvenules, accompaniedby an increase in blood flow in the true capillary network (4). PGEreceptors are subdividedinto four pharmacologicsubtypes : EPl 5 EP2,EP3 (5), and EP4 (6). The EP2 receptor may be involved in the vasodilatation of various blood vessels (7). The EP2 receptor is coupledexclusively to adenylatecyclase via stimulatory G ,. protein (Gs), and consequently, its stimulation activates cyclic AMP formation as a second messenger. Thevasodilatory action of PGE! is mediated via an opening of ATP-sensitive K+ channels (8). Because sulfonylureas inhibit the ATP-sensitive K+ channels, they have the potential to inhibit the vasodilatory action of PGE^Therefore, we excluded patients treated with sulfonylureas from the present study. Denton et al demonstrated that PGEj selectively reduces the cerebrovascular tone in dogs (9). Nakano et al reported that PGEi increases carotid artery blood flow in dogs (10). However, Yamamotoet al, using 133xenon and lithium-drift silicon detectors, demonstrated that PGEj has a direct vasoconstrictor effect on the cerebral vessels and reduces the rCBF in dogs (1 1). Koyama et al showed that PGE}reduces the CBFin young rabbits (12). Thus, no firm conclusions about the effects of PGEj on CBFcan be made from animal studies. The conflicting results may be due to the differences in the method of administration or to species differences. Heiss divided the changes in rCBF induced by agents acting on cerebral vessels into 5 types: 1) no effect on rCBF, 2) diffuse increase, 3) diffuse decrease, 4) intracerebral steal effect, that is, focal decreases and increases in the residual portion of the brain, and 5) inverse cerebral steal effect, that is, focal increases and decreases in residual portions of the brain (13). In clinical studies, Olesen demonstrated that the intracarotid administration of PGEiincreased the rCBF in all patients, who were studied by the intra-arterial 1 33Xe injection method ( 14). Studying the effect of controlled hypotension induced by the continuous intravenous administration of PGEjin patients undergoing neurosurgery under anesthesia, Sha et al demonstrated that CBF tended to increase in a dose-dependent manner ( 1 5). These patients were unlike ours in that they did not have cerebral infarction. Furthermore, a thermal gradient blood flow meter was used, and the obtained CBFmight have reflected CBFonly in areas where the meter wasplaced. Kamimoto intravenous infusion of Lipo PGEj in patients with acute or subacute focal cerebral ischemia using the 133Xe inhalation method (18). Immediately after the administration of Lipo PGEl9 the rCBF of the ischemic area was increased in some patients, was unchanged in some, and was decreased in others. The fact that the rCBFdecreased in the ischemic areas and increased in the non-ischemic areas, suggested the intracerebral steal phenomenon.
The present study showed that the intravenous administration of PGEj increases the rCBF of the brainstem, cerebellum, and the frontal, temporal, and parietal lobes in patients with chronic cerebral infarction. The rCBF of the occipital lobe, thalamus, and striatum also tended to increase after the administration of PGEj. Moreover, the administration of PGEj significantly increased the rCBF in the non-infarcted area adjacent to infarction. These results indicate that the intravenous administration of PGEi increases the CBFin patients with chronic cerebral infarction without an intracerebral steal phenomenon (19) . PGEj reduced the cerebrovascular resistance in the noninfarcted area adjacent to infarcted areas. The fact that the administration of PGEj in patients with chronic cerebral infarction did not produce an intracerebral steal phenomenonin some patients with acute or subacute focal cerebral ischemia (18) may reflect differences in the sensitivity of vessels to PGEt in chronic, acute, and subacute cerebral ischemia. Though the main purpose of this study was to evaluate the effect of intravenous administration of PGEi on CBFin inpatients with chronic cerebral infarction, the evaluation of improvement in clinical symptoms will need more appropriate protocols in subsequent studies of PGI2. Peroral administration of PGEj derivative or PGEj derivative, which is thought to be a more actual method, is expected to increase CBFin outpatients with chronic cerebral infarction. However, the effect of these derivatives on patients with chronic cerebral infarction has been little studied. Therefore, the present study was designed to confirm in inpatients the evaluation of the effect of PGEj on CBF prior to studies of PGE! derivative or PGI2
derivative.
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